INMED PHARMACEUTICALS INC. Income (Loss) from Continuing Operations, Per Basic Share
INMED PHARMACEUTICALS INC. (INM) reported Income (Loss) from Continuing Operations, Per Basic Share of -$2.84 per share for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. income (loss) from continuing operations, per basic share for the quarter ending 2026-03-31 was -$0.69.
- INMED PHARMACEUTICALS INC. income (loss) from continuing operations, per basic share for the quarter ending 2025-03-31 was -$1.89.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|
| 2026-06-30 | -$2.84 S-4/A · filed 2026-09-09 | ||
| 2026-03-31 | -$0.69 S-4 · filed 2026-07-02 | -$1.64 S-4 · filed 2026-07-02 | |
| 2025-06-30 | -$8.90 S-4/A · filed 2026-09-09 | ||
| 2025-03-31 | -$1.89 S-4 · filed 2026-07-02 | -$8.53 S-4 · filed 2026-07-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |